Andere Sprachen PTC Therapeutics, Inc.

Aktien

A1W0MW

US69366J2006

PTCT

Realtime-Estimate Cboe BZX Andere Börsenplätze 20:00:48 01.05.2024			% 5 Tage	% 1. Jan.
33,47 ^USD	+4,11 %		+32,29 %	+21,01 %

29.04.	PTC THERAPEUTICS, INC. : Morgan Stanley senkt seine Verkaufsbewertung	ZM
26.04.	Sektor-Update: Aktien des Gesundheitswesens steigen am späten Nachmittag	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

North American Morning Briefing : More Earnings -2-	30.04.
Sector Update: Health Care Stocks Edge Higher Late Afternoon	26.04.
Sector Update: Health Care	26.04.
PTC Therapeutics Shares Rise After Better-Than-Expected Q1 Results	26.04.
PTC Therapeutics : Q1 2024 FLS	25.04.
PTC Therapeutics: Q1 Earnings Snapshot	25.04.
Earnings Flash (PTCT) PTC THERAPEUTICS Posts Q1 Revenue $210.1M, vs. Street Est of $163.8M	25.04.
PTC Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	25.04.
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results	25.04.
PTC Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2024	25.04.
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	24.04.
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	23.04.
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results	12.04.
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results	11.04.
PTC Therapeutics Seeks EMA Marketing Authorization for Sepiapterin for Phenylketonuria Treatment	28.03.
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA	28.03.
PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA	28.03.
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza as a Treatment for AADC Deficiency	20.03.
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza? as a Treatment for AADC Deficiency	19.03.
PTC Therapeutics Provides Key Regulatory Updates	19.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen PTC Therapeutics, Inc.

Aktien

A1W0MW

US69366J2006

PTCT

Andere Sprachen

Filter